Drug Profile
Imlifidase - Hansa Biopharma
Alternative Names: EnzE programme - Hansa Biopharma AB; Enzyme-based antibody enhancement programme - Hansa Biopharma AB; HMed-IdeS; IDEFIRIX; Idefirix; IdeS; IgG-degrading enzyme of Streptococcus pyogenes; IgG-endopeptidase; Mac-1; Streptococcal cysteine proteinaseLatest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Hansa Medical AB
- Developer Asklepios BioPharmaceutical; Hansa Biopharma AB; Sarepta Therapeutics
- Class Antibacterials; Antineoplastics; Antirheumatics; Bacterial proteins; Endopeptidases; Immunotherapies
- Mechanism of Action Immunoglobulin inhibitors; Immunostimulants; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Renal transplant rejection
- Phase III Anti-glomerular basement membrane disease
- Phase II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Guillain-Barre syndrome; Thrombotic thrombocytopenic purpura
- Phase I Duchenne muscular dystrophy
- Preclinical Autoimmune disorders; Crigler-Najjar syndrome; Glycogen storage disease type II; Limb girdle muscular dystrophies
- No development reported Cancer
- Discontinued Rheumatoid arthritis; Streptococcal infections
Most Recent Events
- 27 Feb 2024 Hansa Biopharma completes phase-II trial for Guillain-Barre syndrome in United Kingdom, France, and Netherlands (IV) (NCT03943589)
- 06 Jan 2024 Preregistration for Renal transplant rejection (Prevention) in Middle East, North Africa (IV)
- 06 Jan 2024 Hansa Biopharma anticipates completes enrolment in the phase III trial for Anti-glomerular basement membrane disease (anti-GBM disease) in 2025